drugset
drugset / Trial / NCT03125642

Auto Stem Cell Transplant for Lymphoma Patients

NCT03125642 ↗

Phase 2 Recruiting 150 enrolled Masonic Cancer Center, University of Minnesota
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.

Timeline

Start
2017-04-20
Primary completion
2026-09-30
Completion
2027-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 60 mg/kg Intravenous
Subject Cyclophosphamide Other / unclassified 1500 mg/m2 Intravenous
Subject Cytarabine Small molecule 100 mg/m2 Intravenous
Subject Etoposide Small molecule 100 mg/m2 Intravenous
Subject Etoposide Small molecule 150 mg/m2 Intravenous
Subject Melphalan Small molecule 140 mg/m2 Intravenous
Subject carmustine Small molecule 300 mg/m2 Intravenous
Background filgrastim Protein / enzyme biologic 5 ug/kg Intravenous

Indications

Hodgkins lymphoma non-Hodgkin lymphoma